WO1999055385A3 - Radioimmunpharmaka zur therapie der hepatitis c - Google Patents

Radioimmunpharmaka zur therapie der hepatitis c Download PDF

Info

Publication number
WO1999055385A3
WO1999055385A3 PCT/DE1999/001237 DE9901237W WO9955385A3 WO 1999055385 A3 WO1999055385 A3 WO 1999055385A3 DE 9901237 W DE9901237 W DE 9901237W WO 9955385 A3 WO9955385 A3 WO 9955385A3
Authority
WO
WIPO (PCT)
Prior art keywords
radioimmunoconjugates
fragment
virus
receptor molecule
hcv
Prior art date
Application number
PCT/DE1999/001237
Other languages
English (en)
French (fr)
Other versions
WO1999055385A2 (de
Inventor
Wolfgang Bergter
Ingrid-Corina Bergter
Original Assignee
Wolfgang Bergter
Bergter Ingrid Corina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998118843 external-priority patent/DE19818843A1/de
Application filed by Wolfgang Bergter, Bergter Ingrid Corina filed Critical Wolfgang Bergter
Priority to DE19980730T priority Critical patent/DE19980730D2/de
Priority to AU44979/99A priority patent/AU4497999A/en
Publication of WO1999055385A2 publication Critical patent/WO1999055385A2/de
Publication of WO1999055385A3 publication Critical patent/WO1999055385A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Radioimmunkonjugate zur in-vivo-Elimination virus-replizierender Zellen bei HCV-infizierten Patienten, dadurch gekennzeichnet, dass sie als immunologisch wirksame Komponente a) einen monoklonalen Antikörper bzy dessen Antigen-bindendes Fragment gegen ein auf der Plasmamembran HCV-infizierter Zellen exprimiertes virales oder virusinduziertes Antigen, oder b) ein Rezeltormolekül bzv ein Fragment des Rezeptormoleküls mit Affinität zu einem Epitop der Oberflächenglykoproteine E1 und/oder E2, oder c) ein durch zufällige bzw gezielte Mutagenese modifiziertes Fragment des Rezeptormoleküls mit Affinität zu einemm Epitop der Oberflächenglykoproteine E1 und/oder E2 und dass sie als radioaktive Komponente ein Radioisotop mit kurzer Halbwertszeit und geringer Reichweite, zum Beispiel d) 131J, oder e) 32P, oder f) 90Y, oder g) 89Sr enthält. Zusammen mit pharmazeutischen Trägern und/oder Hilfsstoffen enthalten.
PCT/DE1999/001237 1998-04-28 1999-04-27 Radioimmunpharmaka zur therapie der hepatitis c WO1999055385A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19980730T DE19980730D2 (de) 1998-04-28 1999-04-27 Radioimmunpharmaka zur Therapie der Hepatitis C
AU44979/99A AU4497999A (en) 1998-04-28 1999-04-27 Radioimmunopharmaca for treating hepatitis c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1998118843 DE19818843A1 (de) 1998-03-08 1998-04-28 Radioimmunpharmaka zur Therapie der Hepatitis C
DE19818843.9 1998-04-28

Publications (2)

Publication Number Publication Date
WO1999055385A2 WO1999055385A2 (de) 1999-11-04
WO1999055385A3 true WO1999055385A3 (de) 2000-03-16

Family

ID=7865973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/001237 WO1999055385A2 (de) 1998-04-28 1999-04-27 Radioimmunpharmaka zur therapie der hepatitis c

Country Status (3)

Country Link
AU (1) AU4497999A (de)
DE (1) DE19980730D2 (de)
WO (1) WO1999055385A2 (de)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
WO1993016192A1 (en) * 1992-02-11 1993-08-19 The Wellcome Foundation Limited Humanised antibody against hepatitis
WO1994004191A1 (en) * 1992-08-13 1994-03-03 Antisoma Limited Medical treatment
WO1994025601A2 (en) * 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
WO1996013590A2 (en) * 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
WO1993016192A1 (en) * 1992-02-11 1993-08-19 The Wellcome Foundation Limited Humanised antibody against hepatitis
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
WO1994004191A1 (en) * 1992-08-13 1994-03-03 Antisoma Limited Medical treatment
WO1994025601A2 (en) * 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
WO1996013590A2 (en) * 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents

Also Published As

Publication number Publication date
WO1999055385A2 (de) 1999-11-04
DE19980730D2 (de) 2001-05-10
AU4497999A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
Yan et al. Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model
ATE239756T1 (de) Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)
EP0608261A4 (de) Zusammensetzung aus einem immunreaktiven hepatitis-c-virus-polypeptid.
DK0676467T3 (da) Europæiske vaccinestammer af det porcine reproduktive respiratoriske syndromvirus (PRRSV)
WO1999050301A3 (en) Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
DE69232906T2 (de) Detektion des Hepatis-C Virus.
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
EP0717104A3 (de) Immuntests von nicht-A, nicht-B Hepatitisvirus-verwandten Antigenen, monoklonale Antikörper und diese synthetisierende Hybridome
WO1997040147A8 (en) Antigenically reactive regions of the hepatitis a virus polyprotein
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
ATE162553T1 (de) Monoklonale antikörper gegen hepatitis-c-virus
WO1999055385A3 (de) Radioimmunpharmaka zur therapie der hepatitis c
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
DE69225960T2 (de) Monoklonale antikörper gegen mögliche hcv-hüllregionen und methoden diese zu benutzen
WO2003040341A3 (en) Anti-hepatitis a virus antibodies
WO2000000223A3 (de) ANTIVIRALE UND ANTIRETROVIRALE RADIOIMMUNPHARMAKA AUF DER BASIS VON α- UND β-STRAHLERN
WO2003011907A3 (de) Rezeptor, dessen verwendung sowie mausantikörper
NO953749L (no) Hepatitt B-escapemutantspesifikke bindingsmolekyler
GR3030212T3 (en) Platelet activating factor antagonists.
Sallberg et al. The Antigen/Antibody Specificity Exchanger: A New Peptide-Based Tool for Re-directing Antibodies of Other Specificities to Recognize the V3 Domain of HIV-1 GP120
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
Ha et al. De novo superinfection of hepatitis B virus in an anti-HBs positive patient with recurrent hepatitis C following liver transplantation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REF Corresponds to

Ref document number: 19980730

Country of ref document: DE

Date of ref document: 20010510

WWE Wipo information: entry into national phase

Ref document number: 19980730

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase